LONDON - eTradeWire -- Partners4Access (P4A), a leading global consultancy specializing in market access for orphan drugs, gene therapies, and rare disease treatments, is excited to announce that three of its poster abstracts have been accepted for presentation at the upcoming ISPOR EU 2024 conference, one of the most prominent global events for health economics and outcomes research (HEOR). The conference will take place in Barcelona, Spain, from 17th - 20th November.

The accepted poster abstracts cover critical topics in the evolving landscape of gene therapy, cost-effectiveness analysis, and payer perceptions, showcasing P4A's dedication to advancing knowledge in these crucial areas of healthcare. The titles of the accepted posters are as follows:

1. What Are the Key Themes and Sentiments Captured through Social Listening in Response to Recent Changes in the Duchenne Muscular Dystrophy Treatment Landscape?
• This poster delves into the insights gathered from social listening to understand the key themes and sentiments among stakeholders following recent developments in the treatment options for Duchenne Muscular Dystrophy.
2. The Key to Success for Estimating Durability in Cost-Effectiveness-Focused Markets
• This research explores the methodologies and challenges in estimating the durability of new therapies, particularly in markets where cost-effectiveness is a primary consideration for payer decision-making.
3. Payer Perceptions of Supportive Evidence in the Estimation of Long-Term Durability for Gene Therapies in Major European Markets
• This poster presents findings on how payers in major European markets perceive the evidence supporting the long-term durability of gene therapies, offering insights into the factors that influence reimbursement decisions.

"We are thrilled to have our research recognized at ISPOR EU 2024," said Sophie Schmitz, Managing Partner at Partners4Access. "These studies reflect our ongoing commitment to addressing the critical challenges in market access for innovative therapies, and we look forward to sharing our findings with the global HEOR community."

More on eTradeWire News

• Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
• Nearly One Million Prisoner Engagements—"30in3" Campaign Near
• Morton Enclosures Boosts UL 891 & UL 508A Panel Support Across Texas–Southeast
• Mend Colorado Reminds Boulder Residents of Expert Solutions for Back, Shoulder, and Knee Pain
• Things to do in Vero Beach FL. This 2025 Summer

Partners4Access invites conference attendees to visit their posters to learn more about these important studies and engage in discussions with the research team.

About Partners4Access

Partners4Access (P4A) is a specialized global consultancy focused on providing market access, pricing, and reimbursement solutions for orphan drugs, cell and gene therapies, and other rare disease treatments. With a mission to improve patient access to life-changing therapies, P4A works closely with pharmaceutical and biotech companies to navigate the complex landscape of rare diseases, ensuring successful market entry and sustainable patient access.

For more information, visit www.partners4access.com.